REPLY
20.12.2023 09:31:34 CET | Business Wire | Press release
Concept Reply, part of the Reply network of companies and specialised in IoT, is working with MULTIVAC, a leading manufacturer of processing and packaging solutions, to develop smart services for automated machine monitoring. This project is part of the Open Industry 4.0 Alliance initiative, in which industry-specific companies have joined forces to develop common standards for the transformation to the Industrial Internet of Things.
As a member of the Open Industry 4.0 Alliance, Concept Reply contributes its expertise to IoT projects and actively supports the setting of standards in the field of Industrial IoT. In this context, Concept Reply is successfully working for international founding member MULTIVAC on the "smart services" project. This cloud IoT project aims to digitally manage machines - both locally and remotely - to make processes more transparent and to increase the efficiency and productivity of systems.
The cloud IoT platform implemented for MULTIVAC acts as a central monitoring and management instance. The data is processed on the platform and made available to users as smart services in freely configurable dashboards. The use of a micro-front-end architecture on the Azure cloud and the application of modern web technologies form the basis for the future use of AI-based assistants, thus laying the foundation for new business models and a sustainable, resource-efficient smart factory. The combination of cloud & edge computing reduces latency from data acquisition to sensor technology and actuator control. The benefits for the user are real-time data processing, protection against cyber-attacks and direct machine-to-machine communication.
Further projects with MULTIVAC are already in the pipeline to expand industry standards through the intelligent digitalisation of production and to actively shape the future of Industry 4.0. Dr Marius Grathwohl, VP Digital Products and Transformation at MULTIVAC and Member of the Board of the Alliance, concluded: "The successful collaboration between Concept Reply and MULTIVAC is based on the commonality of an open mindset and a shared understanding of Industry 4.0. Both companies are members of the Open Industry 4.0 Alliance, and we already have a common understanding of the architecture".
Together with its members, the Open Industry 4.0 Alliance is developing multi-vendor Industry 4.0 solutions and services for automated production systems and warehouses. Use cases include automated onboarding, device provisioning, device management, digital nameplates, digital twins and automated device lifecycle management. The open technical ecosystems enable machines and applications from different vendors to be networked and data to be securely transported along the value chain.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Concept Reply
Concept Reply is an IoT software developer specializing in the research, development and validation of innovative solutions and supports its customers in the automotive, manufacturing, smart infrastructure and other industries in all matters relating to the Internet of Things (IoT) and cloud computing. The goal is to offer end-to-end solutions along the entire value chain: from the definition of an IoT strategy, through testing and quality assurance, to the implementation of a concrete solution. www.concept.reply.com
MULTIVAC Group
Bundled expertise, innovative top technology and strong brands under one roof: The MULTIVAC Group offers complete solutions for the packaging and processing of food, medical and pharmaceutical products as well as industrial goods - and continues to set new standards in the market as a technology leader. For more than 60 years, the name has stood for stability and values, innovation and sustainability, quality and excellent service. Founded in 1961 in the Allgäu region of Germany, the MULTIVAC Group is now a global solutions provider that helps small and medium-sized companies as well as large corporations to organise their production processes efficiently and in a way that conserves resources. www.multivac.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231220017040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom